Paper6470751
Phase II study of low-dose recombinant leukocyte A interferon in disseminated malignant melanoma.
Creagan ET and 6 others. J Clin Oncol, 1984. Cited by 84 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Phase II study of low-dose recombinant leukocyte A interferon in disseminated malignant melanoma. Papers, record 6470751. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/6470751
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Phase II study of low-dose recombinant leukocyte A interferon in disseminated malignant melanoma.
- PubMed
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Interferon Type I | Major topic |
| Melanoma | Major topic |
| Skin Neoplasms | Major topic |
| DNA, Recombinant | |
| Drug Evaluation | |
| Female | |
| Humans | |
| Male | |
| Middle Aged | |
| Prognosis |
Source PubMed
Cited by12
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 84 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 29,236,046 | Advances in Proteomic Techniques for Cytokine Analysis: Focus on Melanoma Research. | Int J Mol Sci | 2017 | https://conductscience.org/library/papers/29236046 | PubMed |
| 22,220,281 | Adjuvant therapy: melanoma. | J Skin Cancer | 2011 | https://conductscience.org/library/papers/22220281 | PubMed |
| 20,821,040 | Cancer immunotherapy and nanomedicine. | Pharm Res | 2011 | https://conductscience.org/library/papers/20821040 | PubMed |
| 19,959,212 | The emergence of immunomodulation: combinatorial immunochemotherapy opportunities for the next decade. | Gynecol Oncol | 2010 | https://conductscience.org/library/papers/19959212 | PubMed |
| 8,542,245 | Experience with interferon alpha 2b combined with dacarbazine in the treatment of metastatic malignant melanoma. | Med Oncol | 1995 | https://conductscience.org/library/papers/8542245 | PubMed |
| 8,513,453 | Recombinant interferon alpha-2a in combination with dacarbazine in the treatment of metastatic malignant melanoma: analysis of long-term responding patients. | Cancer Immunol Immunother | 1993 | https://conductscience.org/library/papers/8513453 | PubMed |
| 8,205,559 | A phase II study of combined administration of dacarbazine and carboplatin with home therapy of recombinant interleukin-2 and interferon-alpha 2a in patients with advanced malignant melanoma. | Cancer Immunol Immunother | 1994 | https://conductscience.org/library/papers/8205559 | PubMed |
| 7,681,371 | Interferon-alpha in malignant and viral diseases. A review. | Drugs | 1993 | https://conductscience.org/library/papers/7681371 | PubMed |
| 3,933,818 | A phase I trial of recombinant gamma interferon in patients with cancer. | Cancer Immunol Immunother | 1985 | https://conductscience.org/library/papers/3933818 | PubMed |
| 3,109,737 | Subcutaneous recombinant gamma interferon in cancer patients: toxicity, pharmacokinetics, and immunomodulatory effects. | Cancer Immunol Immunother | 1987 | https://conductscience.org/library/papers/3109737 | PubMed |
| 2,936,447 | Systemic administration of autologous, alloactivated helper-enriched lymphocytes to patients with metastatic melanoma of the lung. A phase I study. | Cancer Immunol Immunother | 1986 | https://conductscience.org/library/papers/2936447 | PubMed |
| 2,425,443 | Interferons: current status and future directions of this prototypic biological. | Springer Semin Immunopathol | 1986 | https://conductscience.org/library/papers/2425443 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/6470751
GET https://conductscience.org/api/papers/v1/6470751/authors